4.6 Article

Oncogenic Role of miR-15a-3p in 13q Amplicon-Driven Colorectal Adenoma-to-Carcinoma Progression

Journal

PLOS ONE
Volume 10, Issue 7, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0132495

Keywords

-

Funding

  1. VUmc Cancer Center Amsterdam (CCA)
  2. DeCoDe project [03O-101]

Ask authors/readers for more resources

Progression from colorectal adenoma to carcinoma is strongly associated with an accumulation of genomic alterations, including gain of chromosome 13. This gain affects the whole q arm and is present in 40%-60% of all colorectal cancers (CRCs). Several genes located at this amplicon are known to be overexpressed in carcinomas due to copy number dosage. A subset of these genes, including the mir-17 similar to 92 cluster, are functionally involved in CRC development. The present study set out to explore whether apart from mir-17 similar to 92, other miRNAs located at the 13q amplicon show a copy number dependent dosage effect that may contribute to 13q-driven colorectal adenoma-to-carcinoma progression. Integration of publically available miRNA expression, target mRNA expression and DNA copy number data from 125 CRCs yielded three miRNAs, miR-15a, -17, and -20a, of which high expression levels were significantly correlated with a 13q gain and which influenced target mRNA expression. These results could be confirmed by qRT-PCR in a series of 100 colon adenomas and carcinomas. Functional analysis of both mature miRNAs encoded by mir-15a, i.e. miR-15a-5p and miR-15a-3p, showed that silencing of miR-15a-3p significantly inhibited viability of CRC cells. Integration of miR-15a expression levels with mRNA expression data of predicted target genes identified mitochondrial uncoupling protein 2 (UCP2) and COP9 signalosome subunit 2 (COPS2) as candidates with significantly decreased expression in CRCs with 13q gain. Upon silencing of miR-15a-3p, mRNA expression of both genes increased in CRC cells, supporting miR-15a-3p mediated regulation of UPC2 and COPS2 expression. In conclusion, significant overexpression of miR-15a-3p due to gain of 13q is functionally relevant in CRC, with UCP2 and COPS2 as candidate target genes. Taken together our findings suggest that miR-15a-3p may contribute to adenoma-to-carcinoma progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors

Berbel L. M. Ykema, Lisanne S. Rigter, Manon C. W. Spaander, Leon M. G. Moons, Tanya M. Bisseling, Berthe M. P. Aleman, Evelien Dekker, Wieke H. M. Verbeek, Ernst J. Kuipers, Jan Paul de Boer, Pieternella J. Lugtenburg, Cecile P. M. Janus, Eefke J. Petersen, Judith M. Roesink, Richard W. M. van der Maazen, Gerrit A. Meijer, Michael Schaapveld, Flora E. van Leeuwen, Beatriz Carvalho, Petur Snaebjornsson, Monique E. van Leerdam

Summary: The study evaluated clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in Hodgkin's lymphoma (HL) survivors who had undergone abdominal radiotherapy and/or procarbazine treatment. Colorectal neoplasia in HL survivors differs from average-risk controls, with AN primarily classified based on polyp size (>=10 mm) and longer follow-up between HL diagnosis and colonoscopy associated with a higher prevalence of AN.

DIGESTIVE ENDOSCOPY (2022)

Article Oncology

Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case-control study

Roel M. M. Bogie, Chantal M. C. le Clercq, Quirinus J. M. Voorham, Martijn Cordes, Daoud Sie, Christian Rausch, Evert van den Broek, Sara D. J. de Vries, Nicole C. T. van Grieken, Robert G. Riedl, Prapto Sastrowijoto, Ernst-Jan Speel, Rein Vos, Bjorn Winkens, Manon van Engeland, Bauke Ylstra, Gerrit A. Meijer, Ad A. M. Masclee, Beatriz Carvalho

Summary: PCCRCs are more commonly located proximally, non-polypoid appearing, early stage, and poorly differentiated compared to DCRCs. They also show significantly less 18q loss and are more commonly CIMP high and MSI. Molecular features associated with sessile serrated lesions and non-polypoid colorectal neoplasms may contribute to the development of PCCRCs.

BRITISH JOURNAL OF CANCER (2022)

Article Gastroenterology & Hepatology

Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Manon de Krijger, Beatriz Carvalho, Christian Rausch, Anne S. Bolijn, Pien M. Delis-van Diemen, Marianne Tijssen, Manon van Engeland, Nahid Mostafavi, Roel M. M. Bogie, Evelien Dekker, Ad A. M. Masclee, Joanne Verheij, Gerrit A. Meijer, Cyriel Y. Ponsioen

Summary: The excessive risk of colorectal carcinoma (CRC) in patients with both primary sclerosing cholangitis and inflammatory bowel disease (IBD) was not explained by an extensive screen of copy number aberrations, mutations, microsatellite instability, and CpG island methylator phenotype status when compared with patients with IBD-CRC and sporadic CRC.

INFLAMMATORY BOWEL DISEASES (2022)

Review Gastroenterology & Hepatology

Lessons From a Systematic Literature Search on Diagnostic DNA Methylation Biomarkers for Colorectal Cancer: How to Increase Research Value and Decrease Research Waste?

Zheng Feng, Cary J. G. Oberije, Alouisa J. P. van de Wetering, Alexander Koch, Kim A. D. Wouters, Nathalie Vaes, Ad A. M. Masclee, Beatriz Carvalho, Gerrit A. Meijer, Maurice P. Zeegers, James G. Herman, Veerle Melotte, Manon van Engeland, Kim M. Smits

Summary: A systematic literature search revealed that major requirements for the development of clinically relevant diagnostic CRC DNA methylation markers are often lacking. To avoid research waste, clinical needs, intended biomarker use, and independent validation should be better considered before study design. Additionally, improved reporting quality would facilitate meta-analysis, increasing the level of evidence and enabling clinical translation.

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2022)

Article Oncology

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S. M. E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B. A. G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen

Summary: This study established PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. The biomarker showed high sensitivity and specificity, and had a high negative predictive value in identifying patients without clinical benefit. Additionally, high levels of PD-1T TILs were associated with longer progression-free and overall survival.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice

Kris G. Samsom, Luuk J. Schipper, Paul Roepman, Linda J. W. Bosch, Ferry Lalezari, Elisabeth G. Klompenhouwer, Adrianus J. de Langen, Tineke E. Buffart, Immy Riethorst, Lieke Schoenmaker, Daoin Schout, Vincent van der Noort, Jose G. van den Berg, Ewart de Bruijn, Jacobus J. M. van der Hoeven, Hans van Snellenberg, Lizet E. van der Kolk, Edwin Cuppen, Emile E. Voest, Gerrit A. Meijer, Kim Monkhorst

Summary: This study aimed to evaluate the feasibility and efficacy of whole-genome sequencing (WGS) in routine clinical practice. The results showed that WGS can be successfully applied to patients with metastatic cancer, providing comprehensive genomic profiling for the majority of patients and identifying actionable biomarkers and treatment options.

JOURNAL OF PATHOLOGY (2022)

Article Gastroenterology & Hepatology

Initial Impact of National CRC Screening on Incidence and Advanced Colorectal Cancer

Myrtle F. Krul, Marloes A. G. Elferink, Niels F. M. Kok, Evelien Dekker, Iris Lansdorp-Vogelaar, Gerrit A. Meijer, Iris D. Nagtegaal, Emilie C. H. Breekveldt, Theo J. M. Ruers, Monique E. van Leerdam, Koert F. D. Kuhlmann

Summary: The nationwide CRC screening program in the Netherlands, started in 2014, has shown a significant reduction in the incidence of stage II and IV CRC. Patients with screen-detected CRCs had improved survival and less extensive disease compared to clinically detected cases.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Oncology

Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells

Iris van 't Erve, Jamie E. Medina, Alessandro Leal, Eniko Papp, Jillian Phallen, Vilmos Adleff, Elaine Jiayuee Chiao, Adith S. Arun, Karen Bolhuis, John K. Simmons, Aanavi Karandikar, Kenneth C. Valkenburg, Mark Sausen, Samuel Angiuoli, Robert B. Scharpf, Cornelis J. A. Punt, Gerrit A. Meijer, Victor E. Velculescu, Remond J. A. Fijneman

Summary: The study demonstrates that accurate monitoring of treatment response using ctDNA can be achieved in a tumor tissue-independent manner by combining cfDNA and patient-matched WBC genomic DNA analysis. This approach prevents false-positives caused by germline or hematopoietic variants and provides more predictive information on overall survival compared to standard radiological evaluation. Additionally, ctDNA analysis reveals potential therapy resistance mutations in a significant portion of patients.

CLINICAL CANCER RESEARCH (2023)

Article Pathology

A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice

Astrid Kramer, Ed Schuuring, Daan C. L. Vessies, Paul van der Leest, Maartje J. Geerlings, Pim Rozendal, Mirthe Lanfermeijer, Theodora C. Linders, Leon C. van Kempen, Remond J. A. Fijneman, Marjolijn J. L. Ligtenberg, Gerrit A. Meijer, Daan van den Broek, Valesca P. Retel, Veerle M. H. Coup

Summary: This study developed a micro-costing framework for consistent cost calculation of ctDNA testing. The framework takes into account the complete diagnostic workflow of ctDNA testing, including costs for personnel, materials, equipment, overhead, and failures. Evaluations and case studies were performed, showing a wide range of costs per sample and the sensitivity to platform, setting, and testing volume. An open access tool is provided for laboratory-specific calculations and exploring the total costs and impact of alternative prices or assumptions.

JOURNAL OF MOLECULAR DIAGNOSTICS (2023)

Article Biochemistry & Molecular Biology

Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7

Eline J. H. van Houtum, Esther D. Kers-Rebel, Maaike W. Looman, Erik Hooijberg, Christian Bull, Daniel Granado, Lenneke A. M. Cornelissen, Gosse J. Adema

Summary: Tumors create an immunosuppressive tumor microenvironment by altering protein expression and changing their glycosylation status, like altered expression of sialoglycans. Siglec-7, an inhibitory immune receptor similar to PD-1, is used by cancer cells as a glycoimmune checkpoint to evade the immune system. The exact cellular and molecular conditions required for Siglec-7-mediated immune cell inhibition remain largely unknown.

CELLULAR AND MOLECULAR LIFE SCIENCES (2023)

Article Oncology

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features

Hanne Lefrere, Kat Moore, Giuseppe Floris, Joyce Sanders, Iris M. Seignette, Tycho Bismeijer, Dennis Peters, Annegien Broeks, Erik Hooijberg, Kristel Van Calsteren, Patrick Neven, Ellen Warner, Fedro Alessandro Peccatori, Sibylle Loibl, Charlotte Maggen, Sileny N. Han, Katarzyna J. Jerzak, Daniela Annibali, Diether Lambrechts, Karin E. de Visser, Lodewyk Wessels, Liesbeth Lenaerts, Frederic Amant

Summary: Patients with postweaning postpartum breast cancer (PP-BCPW) have a poor prognosis compared with other types of breast cancer. This study found that PP-BCPW patients with low expression of immunoglobulin genes but high infiltration of plasma B cells have an increased risk of metastasis and death.

CLINICAL CANCER RESEARCH (2023)

Article Gastroenterology & Hepatology

An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles

Robert S. Bresalier, Carlo Senore, Graeme P. Young, James Allison, Robert Benamouzig, Sally Benton, Patrick M. M. Bossuyt, Luis Caro, Beatriz Carvalho, Han-Mo Chiu, Veerle M. H. Coupe, Willemijn de Klaver, Clasine Maria de Klerk, Evelien Dekker, Sunil Dolwani, Callum G. Fraser, William Grady, Lydia Guittet, Samir Gupta, Stephen P. Halloran, Ulrike Haug, Geir Hoff, Steven Itzkowitz, Tim Kortlever, Anastasios Koulaouzidis, Uri Ladabaum, Beatrice Lauby-Secretan, Marcis Leja, Bernard Levin, Theodore Robert Levin, Finlay Macrae, Gerrit A. Meijer, Joshua Melson, Colm O'Morain, Susan Parry, Linda Rabeneck, David F. Ransohoff, Roque Saenz, Hiroshi Saito, Silvia Sanduleanu-Dascalescu, Robert E. Schoen, Kevin Selby, Harminder Singh, Robert J. C. Steele, Joseph J. Y. Sung, Erin Leigh Symonds, Sidney J. Winawer

Summary: New non-invasive tests for colorectal cancer (CRC) are emerging, making it challenging to conduct trials with mortality reduction as the main goal. A formal consensus approach involving experts resulted in the revision of previously established principles and the emergence of twelve new principles. The effectiveness of a new test can be evaluated by comparing it with an established non-invasive test, with the faecal immunochemical test considered as the appropriate comparator. Flexible adjustment of the new test's positivity threshold is desirable to meet different screening goals and requirements. A four-phased approach is proposed for the evaluation of new tests, including small studies, prospective estimation of accuracy, evaluation in screening populations, and monitoring for missed lesions.
Article Oncology

Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial

Hielke M. de Vries, Tynisha S. Rafael, Alberto Gil-Jimenez, Jeantine M. de Feijter, Elise Bekers, Elsbeth van der Laan, Marta Lopez-Yurda, Erik Hooijberg, Annegien Broeks, Dennis Peters, Iris M. Seignette, Floris J. Pos, Simon Horenblas, Bas W. G. van Rhijn, Ekaterina S. Jordanova, Oscar R. Brouwer, Eva Schaake, Michiel S. van der Heijden

Summary: Atezolizumab shows significant antitumor activity in patients with advanced penile cancer, although the 1-year progression-free survival (PFS) did not meet the primary endpoint. Higher PFS is observed in patients with high-risk human papillomavirus-positive tumors and those with high infiltration of intratumoral CD3+CD8+ T cells.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Multidisciplinary Sciences

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Debra Van Egeren, Khushi Kohli, Jeremy L. Warner, Philippe L. Bedard, Gregory Riely, Eva Lepisto, Deborah Schrag, Michele LeNoue-Newton, Paul Catalano, Kenneth L. Kehl, Franziska Michor

Summary: The study found a significant association between TP53 mutations and distant metastasis in non-small cell lung cancer (NSCLC) patients, and TP53 mutations were more prevalent in patients with a history of smoking, suggesting a higher risk of distant metastasis in these patients.

SCIENTIFIC REPORTS (2022)

Letter Oncology

Reply to R. Pham et al

Iris van 't Erve, Cornelis J. A. Punt, Gerrit A. Meijer, Remond J. A. Fijneman

JCO PRECISION ONCOLOGY (2022)

No Data Available